文献速递白血病

新诊断慢性髓性白血病体细胞突变的层级分布及早期随访

Hierarchical distribution of somatic variants in newly diagnosed chronic myeloid leukaemia at diagnosis and early follow-up.
PubMed 文献 · Br J Haematol · 2021-07-01

该前瞻性研究在初诊及早期随访时,对49例慢性期CML患者的bulk白细胞、CD34+CD38+祖细胞和CD34+CD38-干细胞进行18个髓系肿瘤相关基因及BCR-ABL1激酶域突变筛查。9例携带体细胞突变(6例ASXL1、1例SETBP1、1例TP53、1例JAK2),无BCR-ABL1 KD突变;其中7例突变见于多个层级群体。突变动态多随治疗诱导的BCR-ABL1转录本下降而减少,提示突变获得于Ph阳性克隆;仅2例一线治疗失败,突变状态与生存或缓解结局无相关性。

要点

  • 初诊慢性期CML患者中18个髓系肿瘤相关基因突变率为9/49,BCR-ABL1 KD突变未检出。
  • 多数突变存在于多个层级造血群体,且动态随BCR-ABL1转录本下降,提示源于Ph阳性克隆。
  • JAK2 V617F可伴随Ph阴性髓系增殖性肿瘤,且不随BCR-ABL1转录本下降而消失。

核心结论

  • 初诊慢性期CML患者可携带非BCR-ABL1的髓系肿瘤相关基因体细胞突变,但突变状态与生存或缓解结局无相关性。

研究设计与样本

  • 前瞻性研究,纳入49例慢性期CML患者,在初诊及早期随访时筛查bulk白细胞、CD34+CD38+祖细胞和CD34+CD38-干细胞中18个髓系肿瘤相关基因及BCR-ABL1 KD突变。

主要发现

  • 9/49例患者携带体细胞突变:6例ASXL1、1例SETBP1、1例TP53、1例JAK2,未检出BCR-ABL1 KD突变。
  • 7/9例突变见于多个层级群体包括初诊时bulk白细胞;8/9例突变动态反映治疗诱导的BCR-ABL1转录本下降。
  • 1例JAK2 V617F伴随Ph阴性髓系增殖性肿瘤,在BCR-ABL1转录本下降5-log后仍持续存在。
  • 9例突变患者中仅2例一线治疗失败;未发现突变状态与生存或缓解结局的相关性。

临床怎么用

  • 初诊CML可考虑筛查髓系肿瘤相关基因突变以识别合并Ph阴性克隆等情况,但突变状态不应作为预后或治疗选择的依据。

局限性

  • 样本量较小(49例),随访时间限于早期,突变与结局相关性的把握度有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

There is an emerging body of evidence that patients with chronic myeloid leukaemia (CML) may carry not only breakpoint cluster region-Abelson murine leukaemia viral oncogene homologue 1 (BCR-ABL1) kinase domain mutations (BCR-ABL1 KD mutations), but also mutations in other genes. Their occurrence is highest during progression or at failure, but their impact at diagnosis is unclear. In the present study, we prospectively screened for mutations in 18 myeloid neoplasm-associated genes and BCR-ABL1 KD in the following populations: bulk leucocytes, CD34+ CD38+ progenitors and CD34+ CD38- stem cells, at diagnosis and early follow-up. In our cohort of chronic phase CML patients, nine of 49 patients harboured somatic mutations in the following genes: six ASXL1 mutations, one SETBP1, one TP53, one JAK2, but no BCR-ABL1 KD mutations. In seven of the nine patients, mutations were detected in multiple hierarchical populations including bulk leucocytes at diagnosis. The mutation dynamics reflected the BCR-ABL1 transcript decline induced by treatment in eight of the nine cases, suggesting that mutations were acquired in the Philadelphia chromosome (Ph)-positive clone. In one patient, the JAK2 V617F mutation correlated with a concomitant Ph-negative myeloproliferative neoplasm and persisted despite a 5-log reduction of the BCR-ABL1 transcript. Only two of the nine patients with mutations failed first-line therapy. No correlation was found between the mutation status and survival or response outcomes.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Romzova M, Smitalova D, Hynst J, et al. Hierarchical distribution of somatic variants in newly diagnosed chronic myeloid leukaemia at diagnosis and early follow-up. Br J Haematol. 2021. PMID: 34212373. doi:10.1111/bjh.17659

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。